Author | Silva, Thiago Cerqueira | |
Author | Shah, Syed Ahmar | |
Author | Robertson, Chris | |
Author | Sanchez, Mauro | |
Author | Katikireddi, Srinivasa Vittal | |
Author | Oliveira, Vinicius de Araújo | |
Author | Paixão, Enny S. | |
Author | Rudan, Igor | |
Author | Bertoldo Júnior, Juracy | |
Author | Penna, Gerson O. | |
Author | Pearce, Neil | |
Author | Werneck, Guilherme Loureiro | |
Author | Barreto, Mauricio L. | |
Author | Boaventura, Viviane S. | |
Author | Sheikh, Aziz | |
Author | Barral Netto, Manoel | |
Access date | 2023-11-23T14:24:53Z | |
Available date | 2023-11-23T14:24:53Z | |
Document date | 2023 | |
Citation | SILVA, Thiago Cerqueira et al. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and scotland: a testnegative design case–control study. PLoS Med, v. 20, n. 1, p.1-15, 2023. | en_US |
ISSN | 1549-1676 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/61425 | |
Sponsorship | Fundação Oswaldo Cruz. (FIOCRUZ) .
Programa Fazer o Bem Faz Bem.
Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB).
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).
Medical Research Council (MRC).
BREATHE—The Health Data Research Hub for Respiratory Health.
UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK.
Public Health Scotland and Scottish Government Director General Health and Social Care and National Core Studies - Immunology.
National Institute for Health Research (NIHR).
Wellcome Trust. | en_US |
Language | eng | en_US |
Publisher | Public Library of Science | en_US |
Rights | open access | en_US |
Subject in Portuguese | Reforçadores de mRNA | en_US |
Subject in Portuguese | BNT162b2 ócia | en_US |
Subject in Portuguese | ChAdOx1 | en_US |
Subject in Portuguese | Infecção sintomática | en_US |
Subject in Portuguese | COVID-19 grave | en_US |
Subject in Portuguese | Brasil | en_US |
Subject in Portuguese | Escócia | en_US |
Title | Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and scotland: a testnegative design case–control study | en_US |
Type | Article | en_US |
DOI | 10.1371/journal.pmed.1004156 | |
Abstract | Background: Brazil and Scotland have used mRNA boosters in their respective populations since September 2021, with Omicron’s emergence accelerating their booster program. Despite this, both countries have reported substantial recent increases in Coronavirus Disease 2019 (COVID-19) cases. The duration of the protection conferred by the booster dose against symptomatic Omicron cases and severe outcomes is unclear. Methods and findings: Using a test-negative design, we analyzed national databases to estimate the vaccine effectiveness (VE) of a primary series (with ChAdOx1 or BNT162b2) plus an mRNA vaccine booster (with BNT162b2 or mRNA-1273) against symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death) during the period of Omicron dominance in Brazil and Scotland compared to unvaccinated individuals. Additional analyses included stratification by age group (18 to 49, 50 to 64, ≥65). All individuals aged 18 years or older who reported acute respiratory illness symptoms and tested for SARS-CoV-2 infection between January 1, 2022, and April 23, 2022, in Brazil and Scotland were eligible for the study. At 14 to 29 days after the mRNA booster, the VE against symptomatic SARS-CoV-2 infection of ChAdOx1 plus BNT162b2 booster was 51.6%, (95% confidence interval (CI): [51.0, 52.2], p < 0.001) in Brazil and 67.1% (95% CI [65.5, 68.5], p < 0.001) in Scotland. At ≥4 months, protection against symptomatic infection waned to 4.2% (95% CI [0.7, 7.6], p = 0.02) in Brazil and 37.4% (95% CI [33.8, 40.9], p < 0.001) in Scotland. VE against severe outcomes in Brazil was 93.5% (95% CI [93.0, 94.0], p < 0.001) at 14 to 29 days post-booster, decreasing to 82.3% (95% CI [79.7, 84.7], p < 0.001) and 98.3% (95% CI [87.3, 99.8], p < 0.001) to 77.8% (95% CI [51.4, 89.9], p < 0.001) in Scotland for the same periods. Similar results were obtained with the primary series of BNT162b2 plus homologous booster. Potential limitations of this study were that we assumed that all cases included in the analysis were due to the Omicron variant based on the period of dominance and the limited follow-up time since the booster dose. Conclusions: We observed that mRNA boosters after a primary vaccination course with either mRNA or viral-vector vaccines provided modest, short-lived protection against symptomatic infection with Omicron but substantial and more sustained protection against severe COVID-19 outcomes for at least 3 months. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil. | en_US |
Affilliation | Usher Institute. University of Edinburgh. Edinburgh. United Kingdom. | en_US |
Affilliation | Public Health Scotland. Glasgow, United Kingdom / MRC/CSO Social & Public Health Sciences Unit. University of Glasgow. Glasgow, United Kingdom. | en_US |
Affilliation | Universidade de Brasília. Brasília, DF, Brasil. | en_US |
Affilliation | Public Health Scotland. Glasgow, United Kingdom / MRC/CSO Social & Public Health Sciences Unit. University of Glasgow, Glasgow, United Kingdom. | en_US |
Affilliation | Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil. | en_US |
Affilliation | London School of Hygiene and Tropical Medicine, London, United Kingdom. | en_US |
Affilliation | Usher Institute. University of Edinburgh. Edinburgh. United Kingdom. | en_US |
Affilliation | Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil. | en_US |
Affilliation | Universidade de Brasília. Brasília, DF, Brasil. | en_US |
Affilliation | London School of Hygiene and Tropical Medicine, London, United Kingdom. | en_US |
Affilliation | Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil. | en_US |
Affilliation | Usher Institute. University of Edinburgh. Edinburgh. United Kingdom. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil. | en_US |
Subject | mRNA boosters | en_US |
Subject | BNT162b2 | en_US |
Subject | ChAdOx1 | en_US |
Subject | Symptomatic infection | en_US |
Subject | Severe COVID-19 | en_US |
Subject | Brazil | en_US |
Subject | Scotland | en_US |
DeCS | RNA Mensageiro | en_US |
DeCS | Vacina BNT162 | en_US |
DeCS | ChAdOx1 nCoV-19 | en_US |
DeCS | Infecções | en_US |
DeCS | COVID-19 | en_US |
DeCS | Brasil | en_US |
DeCS | Escócia | en_US |